Tag:

Regeneron

Latest Headlines

Latest Headlines

Regeneron, Alnylam help drive a $2B spike in biotech R&D spending

While many Big Pharma companies continued to whittle away at their multibillion-dollar R&D operations over the past year, laying off thousands of researchers, a group of midcap biotechs is helping to pick up the slack, according to a new report from GlobalData. And some big spenders like Regeneron and Alnylam led the way, helping drive up the group's total research spending by $2 billion, or 26%, to $9.7 billion.

New drug partnerships in Cuba? Regeneron's chief will be on the spot

As tensions begin to ease between the U.S. and Cuba, partnership opportunities may arise for stateside drugmakers--and Regeneron CEO Len Schleifer is heading down to the country to help get the ball rolling.

Mid-cap biotech beats most of the big dogs with 21.9% revenue growth

Who says bigger is better? According to a new report, mid-cap biotech companies are doing pretty well for themselves, thank you very much.

Opdivo, Praluent and LCZ-696 top a launch crop poised for $27B in sales

What's better than a new drug launch? A launch destined for greatness, of course. For sales and marketing teams, that's about as much job security as you can get. 

Regeneron chief nabs $42M, but he'll have to pay his own club fees this year

Regeneron chief Len Schleifer has topped the ranks of biopharma's highest-paid skippers for the past couple of years now, and though his salary may be rising still, being CEO doesn't quite come with all the perks it used to.

Amgen scores a victory for PCSK9, halving cardio risks after one year

A new generation of cardiovascular drugs has proved itself capable of lowering bad cholesterol across dozens of Phase III trials, but many physicians are holding out to see whether doing so can meaningfully improve patients' lives. In an early peek at some long-term data, one such injected therapy from Amgen halved the risk of major cardiovascular problems after one year of treatment, bolstering the case for the whole class of drugs.

Exclusive: Regeneron, Sanofi outline promising PhIIb data for top blockbuster pick dupilumab

Regeneron and its close partner Sanofi have posted another set of promising results for dupilumab--which targets the interleukin-4 and interleukin-13 inflammatory proteins--from a Phase IIb study that backs up those high expectations.

Regeneron's Eylea beats Roche's Lucentis in new head-to-head study

Regeneron's eye drug Eylea picked up steam against two competing products from Roche, as the first head-to-head study comparing the meds found that Eylea outperformed Lucentis and Avastin in treating moderate to severe vision loss in patients with diabetic macular edema.

Regeneron says its allergy drug could be as big as PCSK9 blockers

The antibody experts at Regeneron believe their in-development allergy treatment could be the next big thing at the Big Biotech, rolling toward the market with a potential blockbuster.

Sanofi, Regeneron capture a shot at first-mover advantage in the PCSK9 market

Amgen just lost a key regulatory race. Armed with a handy FDA shortcut voucher, Regeneron and its Big Pharma partner Sanofi announced today that the agency has accepted their application for the powerful new PCSK9 cholesterol drug alirocumab and set a priority deadline of July 24 for their marketing decision. If they get a quick green light, as many analysts expect, their decision to buy the priority review voucher will be rewarded with first-mover advantage with U.S. payers as Amgen sits out an FDA game clock that ends August 27.